Clareo Health | Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer
Measurable disease according to the RECIST 1.1 guideline
ECOG performance status \<3.
Disease requiring IV chemotherapy (5 Fluorouracil +/- oxaliplatin +/- irinotecan) +/- targeted therapy (cetuximab or panitumumab or bevacizumab) every 14 days
No prior chemotherapy for this adenocarcinoma with the exception of adjuvant chemotherapy
Signed and dated informed consent document.
You may not be if
Medical history of cancer within 5 years
Medical contraindication for a treatment consisted of IV chemotherapy (5 Fluorouracil +/- oxaliplatin +/- irinotecan) +/- targeted therapy (cetuximab or panitumumab or bevacizumab)
Patient with known psychiatric or substance abuse disorders that could interfere with cooperation with the requirements of the study
